New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2014
07:04 EDTEBSEmergent announces waiting period expiration for Cangene acquisition
Emergent BioSolutions announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, in connection with Emergentís proposed acquisition of Cangene has expired. The expiration of the waiting period for antitrust review of the proposed acquisition satisfies one of the conditions to the closing of the acquisition. As announced on December 11, 2013, Emergent and Cangene have entered into a definitive agreement under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222M. Completion of the acquisition is subject to approval by 66 2/3% of the votes cast by Cangene shareholders at a special shareholder meeting scheduled for February 12, approval by the Ontario Superior Court of Justice at a hearing scheduled for February 18 and other customary closing conditions. The transaction is expected to close before the end of1Q14.
News For EBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
16:08 EDTEBSEmergent BioSolutions reaffirms outlook for 2015
Emergent BioSolutions reaffirms its previous 2015 forecast of total revenues of $510M-$540M, driven by BioThrax sales which are anticipated to be between $270M-$285M. The company also forecasts full year 2015 GAAP net income of $50M-$60M and adjusted net income of $60M-$70M.
16:06 EDTEBSEmergent BioSolutions sees Q1 revenue $62M-$62M, one estimate $51.5M
Subscribe for More Information
16:06 EDTEBSEmergent BioSolutions resumes full manufacturing operations of BioThrax
Emergent BioSolutions announced that it has resumed full manufacturing operations of BioThrax after completing its internal manufacturing investigation of foreign particles discovered in a limited number of vials in two manufactured BioThrax lots. It stated, "Following a comprehensive assessment, the company has identified a supplier component as the most probable root cause. As a result, the company is implementing certain targeted corrective and preventive actions in the operations of its suppliers and contract manufacturers, as well as its own operations. The investigation concluded that there was no impact to any BioThrax in distribution or to any of the company's other products or manufacturing operations, including the company's Building 55 operations and plans for licensure."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use